September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Imaging Choroidal Neovascularization with OCTA
Author Affiliations & Notes
  • David Sarraf
    Ophthalmology, UCLA , Los Angeles, California, United States
    Stein Eye Institute, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   David Sarraf, Genentech (F), Optovue (F), Regeneron (F)
  • Footnotes
    Support  Optovue granted OCTA machine for research purposes. Regeneron and Genentech provided research grants unrelated to this presentation.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David Sarraf; Imaging Choroidal Neovascularization with OCTA. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : OCT angiography (OCTA) OCT is a novel imaging modality that employs amplitude or phase decorrelation technology with high-frequency and dense volumetric scanning to detect the motion of blood flow, allowing direct visualization of blood vessels in vivo without the use of exogenous dyes. Unlike fluorescein or indocyanine angiography, depth resolved visualization of normal and abnormal microvascular structures of the retina and choroid may be achieved. This presentation will review the OCTA results of the detailed morphological analysis of type 1 neovascular lesions originating from the choroid and located under the retinal pigment epithelium. The results of the OCTA structural analysis of type 3 intraretinal neovascular complexes, that originate from the deep retinal capillary plexus, will also be presented and these findings will be compared with the OCTA analysis of type 1 lesions. Further, we will summarize the quantitative and qualitative OCTA findings of both type 1 and type 3 neovascular lesions before and after antiVEGF therapy and provide parameters that may be valuable in the future application of OCTA for the optimal evaluation and management of neovascular age related macular degeneration (AMD).

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.